GBT Announces New Employment Inducement Grants
Global Blood Therapeutics (GBT) granted restricted stock units totaling 30,450 shares to 10 new employees on August 1, 2022. This action was part of GBT’s Amended and Restated 2017 Inducement Equity Plan, aimed at attracting talent in compliance with NASDAQ rules. GBT, focused on treatments for sickle cell disease, is advancing its pipeline with therapies like Oxbryta and inclacumab. The company continues to explore innovative treatments for underserved patient communities.
- Attracting talent through restricted stock units, which can enhance employee retention and motivation.
- Continued focus on a promising pipeline for sickle cell disease, potentially leading to increased revenue in the future.
- None.
SOUTH SAN FRANCISCO, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on August 1, 2022, the compensation committee of GBT’s board of directors granted 10 new employees restricted stock units for an aggregate of 30,450 shares of the company’s common stock. These awards were made under GBT’s Amended and Restated 2017 Inducement Equity Plan (the Plan).
The above-described awards were each granted as an inducement material to the employees entering into employment with the company in accordance with NASDAQ Listing Rule 5635(c)(4), and were granted pursuant to the terms of the Plan. The Plan was adopted by GBT’s board of directors in January 2017 and has been amended and restated from time to time.
About Global Blood Therapeutics
Global Blood Therapeutics, Inc. (GBT) is a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments that provide hope to underserved patient communities, starting with sickle cell disease (SCD). Founded in 2011, GBT is delivering on its goal to transform the treatment and care of SCD, a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta® (voxelotor), the first FDA-approved medicine that directly inhibits sickle hemoglobin (HbS) polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in Phase 3 development to address pain crises associated with the disease, and GBT021601 (GBT601), the company’s next generation HbS polymerization inhibitor. In addition, GBT’s drug discovery teams are working on new targets to develop the next generation of treatments for SCD. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news.
Contact:
Steven Immergut (media)
650-410-3258
simmergut@gbt.com
Courtney Roberts (investors)
650-351-7881
croberts@gbt.com
FAQ
What stock units were granted by GBT on August 1, 2022?
Why were the stock units granted to new employees?
What is the purpose of GBT's Amended and Restated 2017 Inducement Equity Plan?
What is GBT's focus area in the biopharmaceutical industry?
